SEC Form 4 · accession 0001209191-15-074185
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yuchun Lee
Director
Period of report
Oct 1, 2015
Accepted (ET)
Oct 5, 2015 · 8:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 1, 2015 | M | 1,333 | $57.27 | A | 1,541 | D | |
| Common StockF1,F2,F3 | Oct 1, 2015 | S | 200 | $102.80 | D | 1,341 | D | |
| Common StockF1,F3,F4 | Oct 1, 2015 | S | 700 | $104.79 | D | 641 | D | |
| Common StockF1,F3,F5 | Oct 1, 2015 | S | 225 | $105.79 | D | 416 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $57.27 | Oct 1, 2015 | M | 1,333 | D | — | Sep 13, 2022 | Common Stock | 1,333 | 27,334 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $102.80 (range $102.66 to $102.94).
- F3Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $104.79 (range $104.38 to $105.36).
- F5Open market sales reported on this line occurred at a weighted average price of $105.79 (range $105.74 to $105.85).
- F6The option vests in 16 quarterly installments from 09/14/2012.